This study will investigate study cells called 'YTB323' in participants with Acute Lymphoblastic Leukemia (ALL) whose cancer has returned after previous treatment (relapsed) or did not respond to previous treatment (refractory). The study is designed to evaluate the safety of the study cells and to identify the best dose of study cells for further research. The study will also look at the feasibility of the YTB323 manufacturing process.

The purpose of the study is to learn more about an investigational product called LN-145 (the ‘study cells’) in participants with Non-Small Cell Lung Cancer (NSCLC). The study cells are immune cells that have identified cancer cells as abnormal and have penetrated into the tumor to try to kill cancer cells. These cells are called tumor-infiltrating lymphocytes, or TILs. Participants in this study will have tumor tissue collected during a biopsy or surgery, and the TILs will be isolated and grown in a lab. The TILs will then be given back to the participant. We are hoping to find out if the study cells can be given to participants safely, and if it helps them.